Cero Therapeutics Advances Phase 1 Trial of CER-1236 in Acute Myeloid Leukemia
I'm PortAI, I can summarize articles.
CERo Therapeutics Holdings Inc. has provided an update on its Phase 1 trial of CER-1236 for acute myeloid leukemia (AML). The trial has completed the dose-limiting toxicity observation for the second cohort's first patient at a higher dose. A second patient in the first cohort received an additional dose. The study aims to evaluate the safety and preliminary efficacy of CER-1236. Enrollment and dosing are ongoing with continued safety monitoring.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments